V
VisCardia
VisCardia Inc is privately held medical device company in Portland Oregon commercializing a proprietary implantable medical therapy
About VisCardia
VisCardia Inc., based in Portland, Oregon, is a privately held medical device developer specializing in innovative therapies for heart failure. The company has developed a novel implantable device therapy known as Synchronized Diaphragmatic Stimulation (SDS) aimed at treating patients with reduced ejection fraction and preserved ventricular synchrony. This therapy offers a minimally invasive alternative to traditional, more complicated surgical procedures, addressing a significant gap in clinical care for heart failure patients who do not respond adequately to drug treatments.
VisCardia's primary market includes cardiology clinics and hospitals, particularly those treating elderly patients who are more prone to heart failure. The business model revolves around the development, clinical testing, and eventual commercialization of its SDS therapy. Revenue generation is expected through the sale of the implantable devices and associated medical services.
The company has completed initial clinical studies in Europe and is actively presenting its findings at major cardiology scientific meetings such as ESC, HFSA, ACC, and AHA. These efforts aim to validate the efficacy and safety of the SDS therapy, paving the way for broader market adoption.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Beaverton, United States
- Employees
- 11
- Open positions
- 2
- Dealroom signal
- 52.3/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, medical implants, Chronic Disease, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Feb 2017 | $13M | $50M | Kinetic Capital | — |
| SEED✓Equity / VC | Jun 2016 | $400K | $1.6M | Undisclosed | — |
Growth signals
Latest recorded traffic for VisCardia is 1K monthly website visits, up 455.6% over the last three months. VisCardia's team grew 37.5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Kinetic Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about VisCardia on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See VisCardia’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.